According to TipRanks.com, Moussatos has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -12.4% and a 31.1% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical, Aquestive Therapeutics, and Pacira Pharmaceuticals.
Currently, the analyst consensus on Liquidia Technologies is a Strong Buy with an average price target of $12.40.
Liquidia Technologies’ market cap is currently $348.7M and has a P/E ratio of -6.83.
Based on the recent corporate insider activity of 15 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of LQDA in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Liquidia Technologies, Inc. is a clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT technology to transform the lives of patients. It operates in two segments: Pharmaceutical Products and Partnering & Licensing. The two product candidates from its pipeline: LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for the treatment of local post-operative pain. Liquidia Technologies was founded in 2004 and is headquartered in Durham, NC.
Read More on LQDA:
- What’s Going on at Recently Listed Lightspeed
- Barrington Reaffirms Their Buy Rating on Calix (CALX)
- Barrington Reaffirms Their Buy Rating on Lemaitre Vascular (LMAT)
- H.C. Wainwright Thinks Karyopharm Therapeutics’ Stock is Going to Recover
- Jefferies Sticks to Their Hold Rating for Marketaxess Holdings (MKTX)